NIB biotec Granted Patent in Canada

NIB Biotec has been granted a patent in Canada for its technology based on the use of urinary biomarkers for the diagnosis of prostate cancer.

This new milestone represents a key strategic step for the company, further strengthening its international position and expanding its intellectual property protection in one of the most advanced markets in healthcare and medical technologies.

NIB Biotec’s patented technology is based on the identification of specific urinary biomarkers, enabling the development of an innovative diagnostic approach: non-invasive, rapid, and more accurate than traditional methods such as the PSA test.

Why Canada Is a Strategic Market

Prostate cancer is a major healthcare challenge in Canada as well. It is the most commonly diagnosed cancer among Canadian men, with approximately 29,300 new cases estimated in 2026, accounting for 23% of all new cancer diagnoses in men, and over 5,300 deaths each year. In addition, it is estimated that 1 in 8 men will develop the disease in their lifetime (source).

Despite the widespread use of PSA-based screening, this approach has significant limitations in terms of specificity and its ability to distinguish between aggressive and indolent forms of the disease. This often leads to overdiagnosis, overtreatment, and a substantial impact on patients’ quality of life as well as on healthcare system costs.

In this context, innovative diagnostic solutions such as the one developed by NIB Biotec address an unmet clinical need by providing more precise tools for risk stratification and patient management, particularly in the setting of active surveillance.

From a market perspective, Canada represents a highly favorable ecosystem for the adoption of innovative technologies: strong healthcare investment, close integration between research and clinical practice, and openness to personalized medicine. Furthermore, the global prostate cancer market is rapidly expanding and is expected to reach approximately $29 billion by 2035, with significant annual growth (source).

In addition, alignment with international standards and participation in the Medical Device Single Audit Program (MDSAP) allow for more efficient multi-country certification processes, making Canada a strategic entry point for global expansion.

Growth and Development Opportunities

The granting of the patent in Canada opens up new opportunities for:

• industrial and commercial partnerships with local and North American companies
• collaborations with leading clinical centers and research institutions
• access to funding programs and investments in healthcare innovation
• accelerated clinical validation pathways and market access

The global market for prostate cancer diagnostics continues to grow rapidly, driven by increasing attention to early detection and precision medicine.

With patent protection now extended to Canada, NIB biotec strengthens its intellectual property portfolio and is well-positioned to move forward into the next phases of development with even greater confidence, reaffirming its commitment to transforming prostate cancer diagnosis on a global scale.